Sign in

Jason Luoma, Ph.D.

@jasonluoma.bsky.social
961 followers 617 following 567 posts

Psychedelics, MDMA, and shame researcher, treatment developer, author, psychologist, and therapy trainer, at the Portland Institute for Psychedelic Science.

PostsRepliesMedia
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 18/05/2026
1 in 10 people who used psychedelics in the past year reported experiencing physical or sexual violence during that use. That's from a new paper I co-authored in World Psychiatry, using a nationally representative US sample. The numbers are sobering.
150
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 18/04/2026
Really resonate with this post about science "I have also stood at the edge of what we know and felt something else entirely. The places where a question opens into a larger question. Where the boundary between what I understand and what I am being asked to become starts to thin...
110
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 20/03/2026
Looks like Osmind's ketamine "me too" formulation is getting closer to FDA approval, to add to esketamine. This time via IV, rather than intranasal. ir.nrxpharma.com/news-release...
ir.nrxpharma.com
110
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 15/03/2026
New in JAMA Network Open: Psilocybin beat the nicotine patch 4-to-1 for smoking cessation (40.5% vs 10% for prolonged abstinence). Important study and impressive headline — but what happens when you look under the hood? A thread to unpack this finding. 🧵#psychedelicscience
141
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 11/03/2026
PIPS is hiring a Research Associate to work on clinical trials of psychedelic-assisted therapy (MDMA, psilocybin). Starting summer 2026. Great for post-bac folks looking for research experience before grad school. portlandpsychotherapy.com/behavioral-science-research-coordinator-in-portland-oregon/
portlandpsychotherapy.com
Research Associate in clinical psychedelic science - Portland Psychotherapy
Join an active clinical research lab at the forefront of psychedelic science. As a Research Associate, you will contribute to multiple clinical trials of Research Associate in clinical psychedelic sci...
010
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 08/03/2026
I was just interviewed on the Mentally Flexible Podcast about ACT and Psychedelics. It was a fun interview and I think covered some interesting ground about shame, transcendent emotions, and psychedelic experience. Hope you enjoy it! podcasts.apple.com/us/podcast/j...
podcasts.apple.com
Jason Luoma, PhD | ACT & Psychedelic Science
Podcast Episode · Mentally Flexible · March 5 · 52m
000
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 19/02/2026
There seem to be a number of sources of data suggest that psychedelics may exert their effects through heightening positive affect and motivational systems (e.g., reward responding), not solely through dampening or reducing negative affect, which is more characteristic of antidepressants. A thread.
241
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 17/02/2026
🧵 First clinical trial ever conducted in a state-regulated psychedelic program just published. Oregon's psilocybin program has served 20,000+ people but the majority are wealthy out-of-state travelers. This study targeted low-income participants to test feasibility. #psychedelicscience
111
Reposted by Jason Luoma, Ph.D.
Bita Moghaddam @bita137.bsky.social · 13/02/2026
approval to study psilocybin/COMP360 assisted therapy for PTSD we shall see if it is more effective than MDMA www.lucid.news/legislation-...
lucid.news
Legislation, Industry, and the Future of Psilocybin for PTSD - Lucid News
The FDA acceptance of Compass Pathway’s Investigational New Drug Application for their COMP360 compound as a possible therapy for PTSD introduces a new area of possible therapies using psilocybin.
0122
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 11/02/2026
Psychedelics are FDA "breakthrough therapies" - but breakthrough for whom? New analysis reveals 85% of US psychedelic trial participants are non-Hispanic White, raising urgent questions about who actually benefits from this "revolution" in mental health. 🧵 #psychedelicscience
150
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 10/02/2026
Important new Nature Medicine review talks about the two neuroscience mechanisms related to psychedelics that appear to be replicating across species, brain scales, and research labs. The story: Acute chaos + lasting plasticity = therapeutic change 🧵#psychedelicscience
120
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 08/02/2026
🌿 Announcing the 2026 Perspective Psychedelic Training Retreat for healthcare professionals July 3-10, 2026 | Netherlands A week-long immersive training in psychedelic-assisted therapy grounded in ACT. Applications open now: perspectiveretreats.com/application-process
perspectiveretreats.com
Application Process | Perspective
120
Reposted by Jason Luoma, Ph.D.
George Takei @georgetakei.bsky.social · 27/01/2026
After being held in two of them as a boy, I fought for decades urging America to never again build concentration camps and put human beings in them. It breaks my heart to watch this happen twice now in my own lifetime.
Screenshot of an X.com post by The Associated Press (@AP) stating that dozens of immigrant families protested for better treatment behind fences at a Texas detention facility, where a 5-year-old Ecuadorian boy and his father were sent after being detained in Minnesota. Below is a video thumbnail showing a crowd gathered outdoors along a fenced walkway; many people wear bright blue or red outerwear, and some hold signs.
6293562112734
Reposted by Jason Luoma, Ph.D.
Princess Vimentin PhD | Cancer Biologist @princess-vimentin.bsky.social · 22/01/2026
🧪IMPORTANT! This graphic explains how science all over the US is funded. Congress approved a 2% increase in the #NIH budget for FY 26. Buried in the bill- Shift of ~40% of grants to MYF. This will still result in a 35% DECREASE in the NUMBER of grants funded per yr. Russel Vought is behind this.
Graphic helps visualize how MYF funds FEWER grants despite the increase in budget approval by Congress.

https://www.researchamerica.org/wp-content/uploads/2025/11/ACT-for-NIH-Multi-Year-Funding-One-Pager_October-2025.pdf
10211142
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 01/01/2026
Fun 2025 post about random facts zhengdongwang.com/2025/12/21/t...
zhengdongwang.com
The best facts I heard this year
Zhengdong Wang’s personal website
010
Reposted by Jason Luoma, Ph.D.
Brian D. Earp, PhD @briandavidearp.bsky.social · 30/12/2025
Psychedelics don’t require ethical exemptions. We argue against “ethical exceptionalism” while supporting context-sensitive policies that uphold shared research and clinical standards. Distinctive effects ≠ new ethics. OA Link: www.researchgate.net/publication/...
researchgate.net
(PDF) Are Psychedelics Ethically Exceptional After All? Some Further Reflections
PDF | In this response to commentators on our target article, we clarify and refine our position on claims of psychedelic ethical exceptionalism.... | Find, read and cite all the research you need on…
062
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 23/12/2025
Our clinical research postdoc in psychedelic science is still receiving applications through January 6th! Come join our awesome team! share.google/8eoBuA33dYa1...
share.google
Postdoctoral Research Fellowship in Clinical Psychedelic Science - Portland Psychotherapy
The Portland Institute for Psychedelic Science and Portland Psychotherapy Clinic, Research, & Training Center are offering a two-year research Postdoctoral Research Fellowship in Clinical Psychedelic ...
020
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 23/12/2025
Great to see some studies coming out on psilocybin for PTSD. Lots of facilitators in Oregon are using psilocybin to treat PTSD, but so far we are lacking data. Only one previous open label trial has been published that I know of. The authors just published a qualitative study from that study. A🧵
460
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 18/12/2025
Ive seen this in papers I've reviewed. People, you can't trust the references that chatgpt generates! That's not how llms work. search.app/CRgw2
search.app
AI Is Inventing Academic Papers That Don't Exist -- And They're Being Cited in Real Journals
Academic articles from authors using large language model are creating an ecosystem of fake research that threatens human knowledge itself.
030
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 17/12/2025
New psilocybin cognition study shows "significant improvements" in processing speed & executive function after treatment. But dig into the data and the picture gets complicated. A thread on why statistical significance does not equal clinical meaningfulness 🧵 #psychedelicscience
150
Reposted by Jason Luoma, Ph.D.
josh hardman @josh-hardman.bsky.social · 15/12/2025
🐁 Very concerning finding: Psilocybin promotes brain tumour growth Authors caution against use of 5-HT2A agonists like psilocybin in patients with glioma, "given the profound and sustained tumor growth-promoting effects observed." Extends to other serotonergic drugs like LSD.
273
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 13/12/2025
Another article about Oregon’s psilocybin system for those interested. From my vantage point seems like the system is relatively stable but probably shrinking some from increased competition from Colorado. Fewer people from the Midwest and east coast these days.
141
Reposted by Jason Luoma, Ph.D.
Alex Kwan @alexkwan.bsky.social · 13/12/2025
This new @michellemonje.bsky.social preprint shows that #psilocybin promotes the rapid and persistent growth of... xenografted glioma in mice. 🫠 www.biorxiv.org/content/10.6... Enduring but maladaptive plasticity induced by #psychedelics. h/t @tylerekins.bsky.social @theborislab.bsky.social
2288
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 05/12/2025
Seems like the The "Memory Wars" are coming back - now with psychedelics. A few studies coming out, this one showing 42% of people with post-psychedelic difficulties linked them to childhood trauma. Centrally, some said they recovered memories they had NO prior recollection of. #psychedelicscience
290
Reposted by Jason Luoma, Ph.D.
Samuli Kangaslampi @kangaslampi.bsky.social · 04/12/2025
Critical commentary on a recent paper reporting emergence of dissociated traumatic memories during psilocybin treatment now out in the Journal of Eating Disorders, with @trpwolff.bsky.social, @manojdoss.bsky.social, Lilian Kloft-Heller, and @henryotgaar.bsky.social. doi.org/10.1186/s403...
doi.org
Questioning the recovery of dissociated traumatic memories under psilocybin: comment on “Therapeutic emergence of dissociated traumatic memories during psilocybin treatment for anorexia nervosa” - Journal of Eating Disorders
In their recent case report article, Peck and colleagues suggested that two patients recovered dissociated traumatic memories during psilocybin treatment for anorexia nervosa. These case reports are of clinical and scientific interest and confirm that psychedelics may induce vivid memory-like experiences. However, the reports warrant scrutiny. Here, based on what is known about recovered memories and the effects of psychedelics, we argue that the authors may not have adequately considered alternative explanations. The cases do not necessarily demonstrate that psilocybin induces recovery of dissociated traumatic memories or could treat dissociative amnesia. We further caution against the authors’ suggestion of explicitly preparing patients for the emergence of forgotten material.
294
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 27/11/2025
Looks like we have a 7th placebo controlled trial on microdosing psychedelics showing microdosing did not outperform placebo, this time for depression. #psychedelicscience www.linkedin.com/posts/justin...
linkedin.com
Microdosing in Depression Trial Initial Results | Justin Hanka | 17 comments
I'm still in disbelief! 😯 After so many years of clinical trials and hope for this treatment for depression, the initial results are in, and its not what we expected or hoped for, but we learned a ...
172
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 14/11/2025
Two more rigorous placebo-controlled trials just came out that were negative on microdosing, this time with psilocybin. I think these are the 5th and 6th RCTs with negative results. NO cognitive or mood benefits compared to placebo. 🧵 #psychedelicscience
130
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 11/11/2025
I had missed this interesting podcast from 2023 with Matt Johnson at Johns Hopkins, talking about his history of psychedelic research and thoughts on his groundbreaking study on psilocybin-assisted therapy for smoking cessation. #psychedelicscience
120
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 10/11/2025
A comprehensive living systematic review on psychedelics & MDMA for mental disorders just launched - this a really important new resource for tracking the evidence in real-time. #psychedelicscience
ebipsyche-database.org
EBI-PSYCHE | Home
110
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 30/10/2025
Super important new paper on reports of challenging experiences by therapists who have participated in research trials of psychedelic-assisted therapy. Reveals huge rift between what providers believe is necessary and what industry is developing as a standard. #psychedelicscience
2102
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 27/10/2025
Strongest data yet suggesting that repeated MDMA use causes deficits in declarative memory (e.g., memory for new information, words, etc). #psychedelicscience #MDMA 10.1093/brain/awaf391
2168
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 19/10/2025
New review says that after 55+ years of psychedelic research, we have very few empirical studies on music selection for psychedelic-assisted therapy—despite experts calling music central to therapeutic outcomes. #psychedelicscience
140
Reposted by Jason Luoma, Ph.D.
Jeremy Berg @jeremymberg.bsky.social · 10/10/2025
Thoughtful and well-informed op-ed from @ianlmorgan.bsky.social Definitely worth a read! www.the-scientist.com/nih-leadersh... 1/2
the-scientist.com
NIH Leadership Is Failing Early Career Researchers
Halted training programs, funding chaos, and hiring freezes jeopardize advancement options for early career researchers.
311558
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 29/09/2025
Interesting commentary on idea of "nondirective" approach in psychedelics as culturally laden. Researchers interviewed therapists in clinical trials and "everybody told us they were totally non-directive." #psychedelicscience
240
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 29/09/2025
Will psychedelic researchers finally speak the same language? A new paper proposes standardized terminology for the field - and some of it is really new - Will it catch on? Here's what they want to change. #psychedelicscienceRetry
120
Reposted by Jason Luoma, Ph.D.
Brian D. Earp, PhD @briandavidearp.bsky.social · 24/09/2025
New publication 🚨 "AI and the Future of Academic Peer Review" - led by Sebastian Porsdam Mann, with @cam.ac.uk Mateo Aboy, Joel Seah, Zhicheng Lin, Xufei Luo, @biowhal.bsky.social, Hazem Zohny, Timo Minssen, and Julian Savulescu: buff.ly/kP5Y6tN
011
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 28/08/2025
An interesting new preprint about self-compassion in psychedelics. Seeing growing research here with Gabrielle Agin-Liebes leading the way. www.researchgate.net/publication/... #psychedelicscience
researchgate.net
(PDF) Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion
PDF | Background: Psychedelics can acutely induce mystical experiences and elevated positive mood, which may contribute to the potential benefits of... | Find, read and cite all the research you need ...
060
Reposted by Jason Luoma, Ph.D.
Parker Singleton @parkersingleton.bsky.social · 18/08/2025
🍄 Our new living systematic review and meta-analysis on psilocybin for depression is out. Here's what we found and the open science infrastructure we built to support it 🧪🧵 www.medrxiv.org/content/10.1...
SYPRES (Synthesis of Psychedelic Research Studies) logo
13724
Reposted by Jason Luoma, Ph.D.
Sean Goldy @seangoldy.bsky.social · 19/08/2025
Love this new review on psychedelics & emotions from colleagues! One theme—how we measure positive emotions— resonates with our paper on why distinct positive emotions need more focus in psychedelic science, given their potential role in therapeutic benefits: www.tandfonline.com/doi/10.1080/...
tandfonline.com
Considering distinct positive emotions in psychedelic science
In this review, we discuss psychedelics’ acute subjective and persisting therapeutic effects, outline the science of positive emotions, and highlight the value in considering distinct positive emot...
041
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 17/08/2025
New study showing that psilocybin can be given to patients on ventilators, dialysis, and with advanced heart failure. Zero serious adverse events occurred further demonstrating that psilocybin can be safe with appropriate medical monitoring. #psychedelicscience
110
Reposted by Jason Luoma, Ph.D.
Dr Paul Liknaitzky @pliknaitzky.bsky.social · 15/08/2025
Applications close in 10 days - don't miss out on this great opportunity! ALSO!!! another research role in our lab coming soon – please subscribe for announcement if you’re not eligible for the current one: www.monash.edu/medicine/scs...
monash.edu
Mailing list subscription
011
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 09/08/2025
New analysis reveals a huge disconnect in MDMA therapy pricing: Lykos wants $36,000 for the drug alone, but researchers calculate it it needs to be around $10,500 to be cost saving. This could be the difference between a niche drug for a few vs a breakthrough therapy accessible to millions.
110
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 31/07/2025
Odds of winning NIH grants plummet as new funding policy and spending delays bite | Science | AAAS share.google/viASDaYC4l6n...
share.google
Odds of winning NIH grants plummet as new funding policy and spending delays bite
Funding multiyear grants up front will sharply cut number of investigators receiving awards
010
Reposted by Jason Luoma, Ph.D.
Matt Wall @mattwall.bsky.social · 11/07/2025
Interesting... MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study www.cambridge.org/core/journal...
cambridge.org
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study | The British Journal of Psychiatry | Cambridge Core
MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study
043
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 30/07/2025
The newest episode of my Research Matters Podcast it out, this time with Louis Castonguay talking about all he's learned forming and managing multiple practice research networks. He was a very entertaining and knowledgeable guest. I learned a ton. jasonluoma.com/podcast/loui... #researchmatterspod
jasonluoma.com
Louis Castonguay, PhD, on Practice Research Networks, Mutual Respect in Science, and the Joy of Collaboration - Jason Luoma, Ph.D.
Episode Description: Louis Castonguay, Ph.D., is a professor of psychology at Penn State University and a leading figure in contemporary psychotherapy research. With a career spanning decades, Dr. Cas...
030
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 30/07/2025
Psychedelics use continues to increase in the USA among people over 25 years old (not for younger cohorts, with a drop in later adolescents. [from 2024 National Survey on Drug Use and Health]
130
Reposted by Jason Luoma, Ph.D.
Eric L. Garland @drericgarland.bsky.social · 27/07/2025
I’m looking for a postdoc to join me at UCSD, ideally a clinical psychologist PhD who can deliver mindfulness interventions as well as write papers and do analyses. I have one of the world’s largest psychophysiology datasets of opioid misuse, OUD, & chronic pain. Competitive salary. DM or email.
279
Reposted by Jason Luoma, Ph.D.
Hugh McGovern PhD @htmcgovern.bsky.social · 23/07/2025
new paper just dropped in Brain and Behaviour, with @bman1285.bsky.social and colleagues: doi.org/10.1002/brb3...
doi.org
Deconstructing Psychedelic Phenomenology: A Thematic Analysis of Discrete Phases of the Psychedelic Experience
A thematic analysis of psychedelic experiences was partitioned into three temporal phases: before, during, and after the experience. Themes before the experience were preparatory intentions and perce...
111
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 22/07/2025
New report commissioned by Harvard reveals psychedelic training programs are in crisis. After MDMA's FDA rejection, it seems like the rush of new psychedelic trainees that was anticipated has stalled.
111
Jason Luoma, Ph.D. @jasonluoma.bsky.social · 22/07/2025
Many people report pain relief from psychedelics in surveys, but rigorous animal testing shows ZERO analgesic effects. This new preprint may reveal something crucial about how psychedelics might actually help with pain. www.biorxiv.org/content/10.1... #psychedelicscience
biorxiv.org
Psilocybin has no immediate or persistent analgesic effect in acute and chronic mouse pain models
The psychedelic psilocybin may have lasting therapeutic effects for patients with chronic pain syndromes. Some clinical and preclinical data suggest these putative benefits derive from direct analgesi...
140